Eisai establishes direct Russian presence
This article was originally published in Scrip
Executive Summary
As part of its continued push into major emerging markets, Eisai has now formally established a new Russian pharmaceutical sales subsidiary in Moscow, through which it plans to begin direct sales and marketing activities for key drugs.